A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Inclusion Criteria:

- Diagnosis of relapsing forms of Multiple Sclerosis

- Patients who will start commercially prescribed fingolimod therapy 0.5mg per day OR
patients already on commercially prescribed fingolimod 0.5mg per day continuously for
≥ 2 years

Exclusion Criteria (per USPI):

- Patients who in the last 6 months experienced myocardial infarction, unstable angina,
stroke, transient ischemic stroke, decompensated heart failure requiring
hospitalization or Class III/IV heart failure

- History or presence of Mobitz Type II second-degree or third-degree atrioventricular
block or sick sinus syndrome, unless patient has a functioning pacemaker

- Baseline QTc interval ≥ 500 msec

- Treatment with Class Ia or Class III anti-arrhythmic drugs

- Patients who have had a hypersensitivity reaction to fingolimod or any of the
excipients

Other protocol-defined inclusion/exclusion criteria may apply